PHARMACY MARKET

Crosscope Inc Allies with Waleed Pharmacy for Pathology Solutions in Oman

Crosscope Inc. | April 11, 2022

Crosscope Inc
Crosscope Inc. teams up with Waleed Pharmacy & Stores LLC. The latter focuses on fetching healthcare, hospital, and pharmaceutical solutions to the Sultanate of Oman, whereas Crosscope provides AI-enabled digital pathology software.

Both have signed Memorandum of Understanding to facilitate a makeover in the Histopathology arena that uses Crosscope’s AI-enabled digital pathology platform. Moreover, both aim to bring pioneering technical solutions to Oman that allows commercial use that will reduce the country's cancer load, which is one of the chief health concern around the world.

Oman is facing severity in terms of Cancer spread, as per World Health Organization. Crosscope Dx comes with an integrated workflow that works on the platform of vendor-agnostic digital pathology, which comes with comprehensive solutions for digital pathology.

Moreover, Crosscope presents features such as advanced workflow, cohesive and easy to follow workflow solutions and open and scalable architecture designed for pathologists to decrease their workload, lessen the reversal time, guarantee quicker diagnosis, and a reduced outbreak of the disease in the region.

Because of this partnership, Waleed Pharmacy will be Crosscope's official representative in Oman. Both firms plan to provide cancer diagnosis service providers with state-of-the-art comprehensive Digital Pathology Platforms, AI, and ML capabilities. They'll also look into all available options for collaboration, collaborating and using each other's knowledge, network, and know-how to improve the region's cancer diagnostics environment.

"We are delighted to join forces with the Waleed Pharmacy group. Waleed Pharmacy's experienced team has a proven track record of delivering and deploying healthcare IT solutions in the Oman region and represents a perfect partner for Crosscope. By teaming up, we are confident that we have created the synergies to boost the development and commercialization of our digital pathology workflows," 

Dr. Jayendra Shinde, CEO of Crosscope

Crosscope may collaborate with the region's most respected key opinion leaders in prestigious hospitals, clinical institutions, diagnostic chains, R&D labs, research organizations, pharma companies, and other organizations in the related space where the company's products provide clinical value to users.

Spotlight

More than 60 people from 16 states have been reported to have measles in the first four months of 2018, says the Centers for Disease Control and Prevention (CDC). New outbreaks continue to add to the number of cases. In 2017, the CDC says 118 people were confirmed with the highly contagious viral disease. "Measles is amongst the most infectious agents we know," says Dr. Pritish Tosh, an infectious diseases specialist at Mayo Clinic.

Spotlight

More than 60 people from 16 states have been reported to have measles in the first four months of 2018, says the Centers for Disease Control and Prevention (CDC). New outbreaks continue to add to the number of cases. In 2017, the CDC says 118 people were confirmed with the highly contagious viral disease. "Measles is amongst the most infectious agents we know," says Dr. Pritish Tosh, an infectious diseases specialist at Mayo Clinic.

Related News

PHARMACY MARKET

Antares Pharma Announces FDA Acceptance of NDA Resubmission for TLANDO®

Antares Pharma, Inc. | February 04, 2022

Antares Pharma, Inc. a specialty pharmaceutical company, announced that the U.S. Food and Drug Administration has accepted its New Drug Application resubmission for TLANDO®, an oral treatment for testosterone replacement therapy. The FDA designated the NDA as a Class 1 resubmission with a two-month review goal period and set a target action date of March 28, 2022, under the Prescription Drug User Fee Act. TLANDO® was granted tentative approval from the FDA as a twice-daily oral formulation of testosterone for testosterone replacement therapy indicated for conditions associated with a deficiency or absence of endogenous testosterone, or hypogonadism in adult males. In granting tentative approval, the FDA concluded that TLANDO® met all required efficacy, quality and safety standards necessary for approval and will be eligible for final approval and marketing in the U.S. upon expiration of the exclusivity period previously granted to Clarus Therapeutics, Inc. for JATENZO® on March 27, 2022. “As we take this final step moving from tentative approval to potential final approval in late March, we will continue to prepare for the commercial launch of TLANDO. Our National Sales Meeting is set for the end of April and will serve as the venue to train and ready our sales professionals to start promoting TLANDO to the medical professionals who treat testosterone deficiency. We are excited to be able to complement our current offering of XYOSTED with an oral formulation to patients and physicians. We will leverage our strong physician relationships which we believe will accelerate the adoption of TLANDO, support our future revenue growth and drive our market share gains in the testosterone market,” Robert F. Apple, President and Chief Executive Officer of Antares Pharma About Antares Pharma Antares Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development and commercialization of self-administered injectable pharmaceutical products using advanced drug delivery auto injector technology. The Company has a portfolio of proprietary and partnered commercial products with several product candidates in various stages of development, as well as significant strategic alliances with industry leading pharmaceutical companies including Teva Pharmaceutical Industries, Ltd. (Teva), AMAG Pharmaceuticals (AMAG), Pfizer Inc. (Pfizer) and Idorsia Pharmaceuticals Ltd. (Idorsia). Antares Pharma’s FDA-approved products include XYOSTED® (testosterone enanthate) injection and Sumatriptan Injection USP, which is distributed by Teva. The Company also markets NOCDURNA® in the U.S. and expects to commercially launch TLANDO® in the U.S. pending final FDA approval.

Read More

BUSINESS INSIGHTS

Harrow Health Acquires Ophthalmic Surgical Drug Candidate From Wakamoto Pharmaceutical Co., Ltd.

Harrow Health, Inc. | August 18, 2021

Harrow Health, Inc. an ophthalmic‑focused healthcare company, today announced that it has entered into an agreement with Wakamoto Pharmaceutical Co., Ltd. to acquire the U.S. and Canadian commercial rights for drug candidate MAQ-100, a preservative-free triamcinolone acetonide ophthalmic injection. MAQ-100 is marketed and sold by Wakamoto in Japan as MaQaid®. Following Japan’s Ministry of Health Labor and Welfare (or MHLW) approval, MaQaid was launched in Japan in 2010, indicated as an intravitreal injection for visualization for vitrectomy. Since its initial MHLW approval, the indication for MaQaid was expanded to include (a) treatments for alleviation of diabetic macular edema, (b) macular edema associated with retinal vein occlusion (or RVO), and (c) non‑infectious uveitis. Harrow intends to leverage the clinical data used for Japanese market approval of MaQaid, initially to support a clinical program and U.S. market NDA submission of MAQ-100 for visualization during vitrectomy. Mark L. Baum, CEO of Harrow Health, stated, “We are indeed honored to work with our new partners at Wakamoto to bring MAQ-100 to the U.S. and Canadian markets. This transaction is an excellent strategic fit with our recent commitment to expand our footprint to include retina‑focused surgeons and follows our recent announcement of the acquisition of AMP‑100, a patented, innovative ocular surface anesthetic drug candidate. Both transactions represent progress towards the execution of our strategic goal to grow Harrow through the addition of high-value products to our pharmaceutical portfolio. And both transactions allow us to leverage our wholly owned, efficient, scalable, and tech‑enabled ImprimisRx ophthalmic-focused platform to expand the portfolio of ophthalmic pharmaceutical products we provide to the thousands of prescribers we serve across the country.” Norihisa Kojima, CEO for Wakamoto Pharmaceuticals, stated, “We are very glad to have an opportunity to collaborate with Harrow Health. We believe Harrow Health’s exclusive focus on ophthalmology and commitment to thousands of American ophthalmic surgeons, providing high‑quality and innovative medications, make Harrow an excellent selection for potential expansion to the U.S. and Canada markets.” Under the terms of the agreement, Wakamoto will receive payments based on the achievement of commercial milestones and supply Harrow with MAQ-100. Harrow Health will have marketing rights for the U.S. and Canada, while Wakamoto Pharmaceuticals will retain MAQ-100 marketing rights in other countries. B. Riley Securities acted as financial advisors to Harrow Health and MP Advisors acted as strategic advisors to Wakamoto on the transaction. About Wakamoto Pharmaceutical Co., Ltd. Wakamoto Pharmaceutical Co., Ltd. (Head office: Tokyo, CEO: Norihisa Kojima), a Japanese pharmaceutical company, started in 1929. Wakamoto Pharmaceuticals manufactures and sells various kinds of ethical drugs in ophthalmology, OTC products and food supplements. About Harrow Health Harrow Health, Inc. is an ophthalmic-focused healthcare company. The Company owns and operates ImprimisRx, one of the nation’s leading ophthalmology-focused pharmaceutical businesses, and Visionology, a direct-to-consumer eye care subsidiary focused on chronic eye disease. Harrow Health also holds non-controlling equity positions in Eton Pharmaceuticals, Surface Ophthalmics and Melt Pharmaceuticals, all of which started as Harrow Health subsidiaries, and owns royalty rights in four clinical-stage drug candidates being developed by Surface Ophthalmics and Melt Pharmaceuticals. For more information about Harrow Health

Read More

RESEARCH

Eli Lilly wins FDA's emergency nod for COVID-19 antibody—but, thanks to mixed data, it's limited

Eli Lilly | November 11, 2020

The U.S. just had another COVID-19 drug authorized for emergency use. But the approval is limited—and, with at least one vaccine launch on the horizon, industry watchers wonder whether drugs to treat the illness have any staying power. The FDA authorized Eli Lilly’s bamlanivimab for emergency use on Monday, making it the first antibody therapy to win that distinction. Dubbed LY-CoV555, it's an anti-SARS-CoV-2 antibody therapy the Indianapolis pharma is co-developing with AbCellera. The OK comes with some caveats: It's limited to patients 12 years and older who aren't hospitalized but who are at high risk of developing severe illness, including elderly people and those with certain underlying conditions. And Lilly is advising infusion within 10 days of symptom onset.

Read More